The two papers published today in Science and Cell have implications for both forensics and genetic research.
Mayo Clinic researchers found that cytogenetic subtypes containing three translocations were more common in individuals with a greater proportion of African ancestry.
The scientists developed a metabolomic panel capable of predicting BMI and identifying subsets of at-risk patients with apparently healthy BMIs.
Researchers reached clinical diagnoses in 35 percent of cases undergoing evaluation over 20 months, sometimes leading to treatment changes.
The three-year extension increases the minimum purchase commitments for the Unyvero system, resulting in an increase in potential revenues of €30 million to Curetis.
In combination with other clinical data, the genomic subtypes were able to predict patients' outcomes and could be used to help guide treatments.
New England Biolabs is using Avacta's affimers with a development-stage research and diagnostic assay that could launch as early as next year.
In addition to the federal grant, the startup has received $125,000 from a Michigan technology fund to help commercialize its GPU-based analysis platform.
The UK Biobank has collected genotyping, medical, and other phenotypic data on nearly 500,000 individuals, which it says will fuel additional studies.
The National Institutes of Health Commercial Accelerator Program helps small healthcare and life science companies bring their products to market.
The new additions reflect data published this summer in the TAILORx trial, which speak to the chemopredictive ability of Genomic Health's Oncotype DX.
The analyst said Myraid's GeneSight and NIPT products present near-term opportunities that "should help power earnings upside in the years to come."
The test is designed to analyze a panel of 112 genes to help in the diagnosis of thyroid nodules with indeterminate fine-needle aspiration cytology.
The company will use the proceeds to complete the development of its its ExoView system for the characterization of exosomes and other extracellular vesicles.
The investment bank said it is encouraged by the company's strong pipeline and position among its competitors but sees further upside for its stock.
Using the publicly available ImmPort database, researchers standardized and analyzed immune-related data for more than 10,300 healthy individuals.
Regenerative therapeutics company StemCyte will offer Fulgent's Beacon Expanded Carrier Screening and Newborn Genetic Analysis testing services.
The technology uses a conducting polymer-based electrochemical chip with an array of electrodes and employs an electrical field to release and detect mutations.
GenAhead said it will use the IP it had licensed from ERS for genome editing applications in pharmaceutical drug discovery and development.
The trial will test two Bristol-Myers Squibb cancer drugs in patients with metastatic or unresectable tumors harboring mutations in the genes POLE and POLD1.
The Fertilome test, a multigene sequencing panel, assesses a number of markers that have been associated with conditions that affect fertility.
Weill Cornell will use Avalon GloboCare's exosome isolation system as part of a workflow to develop the exosomes for clinical studies.
Two investors are alleging Illumina committed fraud through artificial inflation of stock price in connection with its Q3 2016 earnings.
The researchers said that uncovering a genetic mechanism behind the condition could aid in the development of new treatments.
An analysis of post-mortem brain transcripts led to Alzheimer's-related alternative gene splicing and expression events, including those influenced by known risk alleles.
Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.
Wired reports that researchers have shown they could reprogram a DNA-based computer.
Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.
In Science this week: whole-genome sequencing of single sperm cells, and more.